Florida is currently home to 3776 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Miami, Tampa, Jacksonville and Orlando. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Recurrent Wheezing
Recruiting
This study will assess the efficacy and safety of daily OM-85 treatment compared to placebo in children aged 6 months to 5 years with recurrent wheezing
Gender:
ALL
Ages:
Between 6 months and 72 months
Trial Updated:
06/06/2025
Locations: BioMD Clinical Research, Coral Gables, Florida
Conditions: Recurrent Wheezing, Wheezing Lower Respiratory Illness
LGMD R1 Natural History Study
Recruiting
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
Gender:
ALL
Ages:
Between 12 years and 50 years
Trial Updated:
06/06/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Calpain-3 Deficiency Limb Girdle Muscular Dystrophy Type 2A, Limb Girdle Muscular Dystrophy, Limb Girdle Muscular Dystrophy Type R1, LGMD2A
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Recruiting
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: BAPTIST ALLIANCE - MCI (Data Collection Only), Miami, Florida
Conditions: Breast Cancer, Metastatic Triple-Negative Breast Cancer
MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Recruiting
MEKTOVI (binimetinib) is an oral, highly selective reversible inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. The biological activity of binimetinib that has been evaluated bith in vitro and in vivo in a wide variety of tumor types In this Phase II, the drug will be used to treat pediatric patients diagnosed with recurrent Adamantinomatous Craniopharyngioma including patients who have undergone surgery and/or radiation therapy.
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
06/06/2025
Locations: Nicklaus Children's Hospital, Miami, Florida
Conditions: Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Recruiting
This study is researching the experimental drugs called pozelimab and cemdisiran, and cemdisiran monotherapy. The study is focused on patients with generalized myasthenia gravis (gMG). Myasthenia gravis is a disease that causes weakness and fatigue in muscles in the body because the nerves and muscles are not communicating properly. The aim of the study is to see how effective pozelimab and cemdisiran are when used in combination and when pozelimab and cemdisiran are used alone for patients with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: SFM Clinical Research, LLC, Boca Raton, Florida
Conditions: Generalized Myasthenia Gravis
NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies
Recruiting
Multicenter, open-label study in patients with advanced or metastatic solid tumor malignancies to evaluate the safety, tolerability, and preliminary anti-tumor efficacy, PK, and pharmacodynamics of continuously dosed NP-G2-044 monotherapy and NP-G2-044 in combination with anti-PD-1 therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Florida (UF) - Shands Cancer Center, Gainesville, Florida
Conditions: Advanced or Metastatic Solid Tumor Malignancies
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Recruiting
This study will test the safety of ruxolitinib, given at one dose that does not change, and duvelisib, given at different doses, to find out what effects, if any, the study treatment has on people with relapsed or refractory NK-cell or T-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: University of Miami (Data Collection Only), Miami, Florida
Conditions: T-cell Lymphomas, NK-Cell Lymphomas, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocyte Leukemia
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Recruiting
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
Gender:
ALL
Ages:
Between 1 year and 17 years
Trial Updated:
06/06/2025
Locations: Travere Investigational Site, Miami, Florida
Conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, Alport Syndrome, IgA Vasculitis
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Recruiting
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than docetaxel and to assess how safe telisotuzumab vedotin is in adult participants with NSCLC who have previously been treated. Change in disease activity and adverse events will be assessed. Telisotuzum... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Mayo Clinic /ID# 254688, Jacksonville, Florida
Conditions: Non Small Cell Lung Cancer
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
Recruiting
This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Florida Cancer Specialists - Sarasota, Sarasota, Florida
Conditions: Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
Transforaminal Lumbar Interbody Fusion (TLIF)
Recruiting
This is a global, multi-center, prospective, randomized, blinded, controlled pivotal study. Clinical and radiological evaluation will be performed preoperatively and postoperatively up to 24 months; and endpoint success will be determined at 24 months postoperatively. Overall a maximum of 600 subjects will be enrolled and treated. The purpose of the study is to provide safety and effectiveness data of Infuse™ in Transforaminal Lumbar Interbody Fusion (TLIF) procedures and to obtain indication e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/06/2025
Locations: Advent Health Altamonte Springs, Altamonte Springs, Florida
Conditions: Degenerative Disease of the Lumbosacral Spine
A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects
Recruiting
The goal of this prospective, non-randomized, single-arm, feasibility study is to develop data to evaluate the safety and feasibility of ExAblate 4000 treatment of benign intracranial tumors which require clinical intervention in pediatric and young adult subjects. Indication of Use: Ablation of benign intracranial tumors in children and young adults which are ExAblate accessible.
Gender:
ALL
Ages:
Between 5 years and 22 years
Trial Updated:
06/06/2025
Locations: Nicklaus Children's Hospital Insititute, Miami, Florida
Conditions: Benign Centrally-Located Intracranial Tumors